A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

Clinical trial NCT02864251 · COMPLETED

Trial details

NCT number: NCT02864251
Sponsor: Bristol-Myers Squibb
Status: COMPLETED
Phase: Phase 3
Study type: INTERVENTIONAL

Non-Small-Cell Lung Carcinoma

Start date: 2017-03-17
Primary completion: 2022-01-20
Enrollment: 367

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.